Incyte Stock Performance
| INCY Stock | USD 98.91 0.38 0.38% |
On a scale of 0 to 100, Incyte holds a performance score of 9. The company retains a Market Volatility (i.e., Beta) of 0.64, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Incyte's returns are expected to increase less than the market. However, during the bear market, the loss of holding Incyte is expected to be smaller as well. Please check Incyte's potential upside, and the relationship between the jensen alpha and accumulation distribution , to make a quick decision on whether Incyte's current trending patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Incyte are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Incyte showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.35) | Five Day Return (1.46) | Year To Date Return 42.3 | Ten Year Return (9.32) | All Time Return 5.2 K |
Last Split Factor 2:1 | Last Split Date 2000-09-01 |
1 | Disposition of 5233 shares by Stein Steven H of Incyte at 102.2 subject to Rule 16b-3 | 11/14/2025 |
2 | Why Incyte is a Top Momentum Stock for the Long-Term | 11/20/2025 |
3 | Incyte Evaluating Valuation Following Recent Share Price Momentum | 12/01/2025 |
4 | Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients ... | 12/08/2025 |
5 | Incyte Announces Change to its Board of Directors | 12/12/2025 |
6 | CMS Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China | 12/15/2025 |
7 | Disposition of 4323 shares by Michael Morrissey of Incyte at 97.26 subject to Rule 16b-3 | 12/17/2025 |
8 | Disposition of 600 shares by Thomas Tray of Incyte at 98.25 subject to Rule 16b-3 | 12/18/2025 |
9 | Disposition of 1730 shares by Thomas Tray of Incyte at 95.76 subject to Rule 16b-3 | 12/19/2025 |
10 | Incyte Japan gains approval for Minjuvi with rituximab and lenalidomide to treat relapsed follicular lymphoma | 12/22/2025 |
11 | Is It Too Late To Consider Incyte After A 45 percent Rally In 2025 | 12/23/2025 |
12 | Incyte Corporation Nasdaq Index Fund Pathway Science | 12/29/2025 |
| Begin Period Cash Flow | 3.2 B | |
| Total Cashflows From Investing Activities | 157.5 M |
Incyte Relative Risk vs. Return Landscape
If you would invest 8,628 in Incyte on October 2, 2025 and sell it today you would earn a total of 1,263 from holding Incyte or generate 14.64% return on investment over 90 days. Incyte is currently generating 0.2414% in daily expected returns and assumes 2.0733% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Incyte, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Incyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Incyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Incyte, and traders can use it to determine the average amount a Incyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1164
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | INCY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Incyte is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Incyte by adding it to a well-diversified portfolio.
Incyte Fundamentals Growth
Incyte Stock prices reflect investors' perceptions of the future prospects and financial health of Incyte, and Incyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Incyte Stock performance.
| Return On Equity | 0.3 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.25 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 16.77 B | ||||
| Shares Outstanding | 196.32 M | ||||
| Price To Earning | 19.17 X | ||||
| Price To Book | 4.23 X | ||||
| Price To Sales | 4.05 X | ||||
| Revenue | 4.24 B | ||||
| Gross Profit | 2.72 B | ||||
| EBITDA | 408.16 M | ||||
| Net Income | 32.62 M | ||||
| Cash And Equivalents | 2.72 B | ||||
| Cash Per Share | 12.24 X | ||||
| Total Debt | 37.96 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 3.91 X | ||||
| Book Value Per Share | 23.71 X | ||||
| Cash Flow From Operations | 335.34 M | ||||
| Earnings Per Share | 5.90 X | ||||
| Market Capitalization | 19.49 B | ||||
| Total Asset | 5.44 B | ||||
| Retained Earnings | (1.07 B) | ||||
| Working Capital | 1.6 B | ||||
| Current Asset | 842.38 M | ||||
| Current Liabilities | 168.01 M | ||||
About Incyte Performance
Evaluating Incyte's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Incyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Incyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 56.89 | 59.73 | |
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.01 | 0.01 |
Things to note about Incyte performance evaluation
Checking the ongoing alerts about Incyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Incyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Incyte has a strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: Incyte Corporation Nasdaq Index Fund Pathway Science |
- Analyzing Incyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Incyte's stock is overvalued or undervalued compared to its peers.
- Examining Incyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Incyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Incyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Incyte's stock. These opinions can provide insight into Incyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.